Navigation Links
Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
Date:1/12/2009

- Company to Provide Update on Pipeline Efforts at 27th Annual J.P. Morgan Healthcare Conference -

REDWOOD CITY, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) announced today that it has initiated an independent clinical validation study for its 18-gene Oncotype DX(R) colon cancer assay. Utilizing more than 1,200 patient samples from the landmark QUASAR trial, the validation study will use prospectively defined endpoints to assess the clinical utility of the Oncotype DX colon cancer assay to predict likelihood of recurrence for stage II colon cancer patients treated with surgery alone and the magnitude of treatment benefit with chemotherapy following surgery. Results from the study are expected to be reported in the second half of 2009.

Stage II colon cancer (also known as Dukes' Stage B) affects an approximately 30-40,000 people each year in the United States and the current treatment paradigm is unclear. About a third of patients receive adjuvant chemotherapy, usually 5-fluorouracil/leucovorin (5FU/LV) or combinations that include 5FU/LV; however, research indicates that only 2-4 percent benefit from this treatment, which has significant associated toxicity. While there are existing clinical markers traditionally associated with higher-risk in colon cancer patients, there is no clinically validated genomic test available that predicts the likelihood of recurrence or magnitude of chemotherapy benefit for individual patients.

"There is a critical need for more targeted approaches in treating the tens of thousands of patients with stage II colon cancer and the initiation of this study brings us one step closer to delivering a tool that may do that," said Steven Shak, M.D., chief medical officer, Genomic Health. "Over the past two years we have partnered with the National Surgical
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
2. Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
3. AutoGenomics Invited to Present at the 2009 JPMorgan Healthcare Conference
4. Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
5. Transgenomic Receives Accreditation From College of American Pathologists
6. Genomic Health Announces Appointment of Ginger Graham to Board of Directors
7. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
8. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
9. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
10. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
11. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 In support of Swiss contributions ... General of Switzerland in New York is pleased to ... Tûranor PlanetSolar , to Manhattan. PlanetSolar is in ... 2013 tour with scientists on board from the University ... runs exclusively on energy from the sun and eliminates ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 DuPont welcomes ... the 11th annual DuPont National AgriScience Teachers Ambassador Academy ... in Chestertown, Md. , The NATAA ... DuPont and is a special project of the ... of Agricultural Educators (NAAE) . The highly recommended ...
(Date:6/18/2013)... June 18, 2013 ... research firm, announces the initiation of full ... biopharmaceutical company developing and marketing products for ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... examining the investment merits of BioAlliance Pharma, ...
(Date:6/18/2013)... Toronto, Canada (PRWEB) June 18, 2013 ... FDA oversight of pharmaceutical advertising and promotion, and ... , Viewers will learn how to apply these ... enforcement examples:, ,     The fundamentals on ... advertising and promotional labeling ,     Assessing traditional ...
Breaking Biology Technology:Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2
... therapy with Pfizer,s recently ... MALIBU, Calif., Nov. 15 Pathway Diagnostics announces,that ... U.S. Patent,number 7,294,458 (the ,458 patent) entitled "Analysis of ... Pathway Diagnostics,has licensed the ,458 patent (with rights to ...
... WYE ),today announced that its Board of Directors ... effective immediately. Mr. Davidson will,continue in his role as ... and divisional financial positions since joining the Company,in 1984. ... Chief,Financial Officer, Wyeth Consumer Healthcare and Deputy Treasurer, Wyeth. ...
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that ... September 30, 2007. Net,revenues totaled $7,373,770 for the quarter ... in 2006. Gross profit decreased by 2.66% due to ... from Aida,s,transfusion and injection forms of etimicin sulfate increased ...
Cached Biology Technology:Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy 2Aida Files 10Q 2Aida Files 10Q 3Aida Files 10Q 4
(Date:6/18/2013)... Obar, Ph.D., Department of Immunology and Infectious Diseases, Montana ... Young Investigator Award for his research on factors affecting ... , Obar earned his B.A. in Microbiology from ... complete his Ph.D. in Microbiology and Immunology from Dartmouth ... research in Edward Usherwood,s laboratory at the Geisel School ...
(Date:6/18/2013)... A team of internationally recognized feline experts including veterinarians ... the University of Lincoln, U.K. and Dr Ilona Rodan, ... by the International Society of Feline Medicine (ISFM) and ... guidelines for veterinarians, owners and those working with cats ... domestic cat. The new guidelines appear in the ...
(Date:6/17/2013)... LA JOLLA, CA June 17, 2013 An ... Institute (TSRI), the Howard Hughes Medical Institute and Albert ... a highly promising new anti-tuberculosis compound that attacks the ... findings represent an effort to help solve one of ... of TB and its dangerous drug-resistant strains," said Peter ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Joshua Obar 2Feline behavior experts release guidelines to improve the welfare of cats 2New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4
... more serious threat to marine life than previously thought. ... (19 July) in the British Ecological Society,s Journal ... of turtles from across the Pacific are being captured ... fisheries in Peru, the study suggests that thousands of ...
... Those solar panels on top of your roof aren,t ... your workplace, too, according to a team of researchers led ... UC San Diego Jacobs School of Engineering. , In ... Solar Energy , Kleissl and his team published what they ...
... 2011) Researchers from the John Theurer Cancer Center ... cancer-related studies during the recently concluded American Society of ... 3 7, 2011 in Chicago. The studies examined ... outcomes, and patient quality of life issues. ...
Cached Biology News:Study shows small-scale fisheries' impact on marine life 2Solar Panels Keep Buildings Cool 2Solar Panels Keep Buildings Cool 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 2John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 4John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 5John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 6
... Immunogen KLH-conjugated, synthetic ... 47-66 (PAEV-GPGAVGERTPRKKEPP) of human BRAF-HDAC ... (BHC110/LSD1). Quality Assurance ... Stability 2 years ...
Request Info...
...
...
Biology Products: